pharmaceutical investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
pharmaceutical investing Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
pharmaceutical investing Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
pharmaceutical investing Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
pharmaceutical investing Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding
NevGold Announces Up To 53.7% Antimony, And Fourteen Samples Over 2% Antimony, From Surface Sampling On Pre-Strip Dump
TomaGold Completes Extension Drilling Program at Berrigan Mine and Launches Major Prospecting and Geophysical Survey Campaign Across its Chibougamau Properties
